
Conference Coverage
Latest

Jun 22, 2026 | News
The BioPharm Brief: Triple Threats, TL1A Bets, and AI Brains

Improving ADC Tolerability Could Expand Long-Term Cancer Treatment Options
Jun 22, 2026

Innovent's Trispecific Antibody IBI3003 Advances Into Phase 3 for Relapsed or Refractory Multiple Myeloma
Jun 22, 2026

Bionyra Pharma Launches with $165M and Two TL1A Biologics Licensed From TrueLab, Entering Crowded IBD Race
Jun 22, 2026

Insilico Medicine and SK Biopharmaceuticals Form AI-Powered Drug Discovery Collaboration for Neuroimmune CNS Disorders
Jun 22, 2026

Advertisement
Shorts

0:30
Which Would You Choose, Complement Activation or Neutrophil Activity?
2 hours ago
by
Nicholas Jacobus(+1 more)

0:36
One Thing You Discovered in Human Antibody Data That Surprised You
3 hours ago
by
Nicholas Jacobus(+1 more)

0:38
Making Cancer a Chronic Disease: The Shift to Kinder Treatments
5 hours ago
by
Emily Schoenthaler(+1 more)

0:43
The Major Shift from Chemotherapy to Targeted Therapy
11 hours ago
by
Feliza Mirasol(+1 more)

0:33
Building a Billion-Dollar Dream Team
4 days ago
by
Feliza Mirasol(+1 more)

0:43
Hope Behind Positive Kimmtrak Data
10 days ago
by
Emily Schoenthaler(+1 more)

0:38
3D Printing Bones: The Future of Biomedical Engineering
20 days ago
by
Feliza Mirasol(+1 more)

0:35
The Secret to a Thriving Biotech Ecosystem
a month ago
by
Feliza Mirasol(+1 more)

0:31
Don't Compromise Biology for Manufacturing Scalability
a month ago
by
Feliza Mirasol(+1 more)

0:33
Why Great Science Fails without Scale
a month ago
by
Feliza Mirasol(+1 more)
Advertisement
All News
Advertisement

Speaking prior to the start of BIO 2026, Aprea Therapeutics CEO Dr Oren Gilad explains how biomarker-driven oncology strategies are advancing targeted therapies designed to improve efficacy while reducing treatment-related toxicity.

Takeda will use Boltz biomolecular AI models to support structure prediction, affinity estimation, and molecular design in preclinical research.

Japan's Ministry of Health, Labour and Welfare has approved the subcutaneous formulation of isatuximab (Sarclisa) across multiple myeloma treatment lines, making it the second country after the European Union to greenlight the administration route change backed by Phase 3 IRAKLIA trial data — with a US decision now expected by July 23, 2026.



















